Toric multifocal IOL to achieve emmetropia and near vision: one year outcomes

Poster Details

First Author: G.Scaltrini ITALY

Co Author(s):    M. Piovella   B. Kusa           

Abstract Details

Purpose:

To evaluate multifocal toric IOL to manage astigmatism during cataract surgery and achieve emmetropia and near vision.

Setting:

C.M.A. Centro di Microchirurgia Ambulatoriale, Monza, Italy

Methods:

Eyes with cataract and with-the-rule corneal astigmatism (2.38 ± 0.82 D) had AT LISA toric 909M implantation. IOL calculations were performed using Z-CALC online calculator, taking into account the surgeon SIA. IOL axis alignment during surgery was accurately performed. Outcomes measurements were subjective refraction, corneal astigmatism using ATLAS™ 9000 Corneal Topography System or Tomey TMS 2 Corneal Tomographer, visual acuity, contrast sensitivity using OPTEC 6500

Results:

The study included 23 eyes from 16 patients (mean age 51.46 ± 11.12 years [SD]). Preoperatively, mean BCVA and SE were 0.85 ± 0.25 (decimal) and 2.40 ± 3.40 D respectively. Patients presented with a mean corneal cylinder and mean refractive cylinder of 2.38 ± 0.82 D and 1.48 ± 1.26 D respectively. Six months postoperatively, mean monocular UCVA and BCVA were 0.73 ± 0.22 and 0.90 ± 0.18 respectively for far vision. Near monocular UCVA was 20/34. The mean residual refractive cylinder was 0.32 ± 0.31 D. Photopic contrast sensitivity was within the normal range (*B. Hohberger, et al." Measuring Contrast Sensitivity in normal subjects with OPTEC 6500: Influence of Age and Glare" , Graefes Arch Clin Exp Ophthalmol (2007) 245: 1805-1814) for daylight conditions. Similar outcomes were observed in mesopic conditions with or without glare

Conclusions:

AT LISA toric 909M is an advanced generation multifocal IOL preferably indicated for bilateral implantation. Initial clinical outcomes indicate that this is a new effective multifocal design. FINANCIAL DISCLOSURE?: ... receives consulting fees, retainer, or contract payments from a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented